PBAC's latest decision on Tenofovir with emtricitabine: Recommended with restriction (2017). Considered for Pre-exposure prophylaxis (PrEP) against HIV in adults at medium to high risk of infection.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
$153k/QALY
Range: $104k/QALY–$153k/QALY
Submissions
1
first 2017
Submissions
1
2017 → 2017
Eligible population
Adults 18 years or older at medium to high risk of HIV infection, as defined by updated Australian Society for HIV Medicine Guidelines, who return a negative HIV test prior to initiating treatment and continue to return negative HIV tests at 3 monthly intervals.
Therapy area
Infectious disease
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
standard of care (combination of safe sex practices)